Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.
Alimera Sciences’ primary focus is on ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection.1
ILUVIEN has received FDA approval in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.1
ILUVIEN has received marketing authorization approvals in Austria, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden and the United Kingdom.
Alimera has received a positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 7 European Union countries.
The regulatory process for these additional countries, consisting of Ireland, the Netherlands, Belgium, Luxembourg, Finland, Poland and the Czech Republic, will now enter the national phase in which each country grants marketing authorization.